Biblio

Author Title [ Type

] Year

Filters: Author is Casasnovas, Olivier [Clear All Filters]

Journal Article

Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K, Thieblemont C, Cacheux V, Cartron G, Compain L, et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol. 2014;93(2):233-42.

Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. Nat Med. 2023.

Ghesquières H, Dalban C, Nicolas-Virelizier E, Jardin F, Le Bras F, Le Gouill S, Casasnovas O, Vizoso S, Hernandez C, Metzger S, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres. Br J Haematol. 2021.

Thieblemont C, Altmann B, Frontzek F, Renaud L, Chartier L, Ketterer N, Recher C, Poeschel V, Fitoussi O, Held G, et al. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/ DSHNHL analysis. Blood Adv. 2023.

Van Den Neste E, Casasnovas O, André M, Touati M, Senecal D, Edeline V, Stamatoullas A, Fornecker L, Deau B, Gastinne T, et al. Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98(8):1185-95.

Sesques P, Bourcier J, Golfier C, Lebras L, Nicolas-Virelizier E, Hacini M, Perrin MClaire, Voillat L, Bachy E, Traverse-Glehen A, et al. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Hematol Oncol. 2020.

Manson G, Mear J-B, Herbaux C, Schiano J-M, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C, et al. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer. 2019;115:47-56.

Sarkozy C, Thieblemont C, Obéric L, Moreau A, Bouabdallah K, Damaj G, Gastinne T, Tessoulin B, Ribrag V, Casasnovas O, et al. Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study. J Clin Oncol. 2023:JCO2301586.

Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023.

Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511-e522.

Alig S, Macaulay CW, Kurtz DM, Dührsen U, Hüttmann A, Schmitz C, Jin MC, Sworder BJ, Garofalo A, Esfahani MShahrokh, et al. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2021:JCO2002573.